|
1
|
Sherr CJ: Mammalian G1 cyclins. Cell.
73:1059–1065. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Malumbres M and Barbacid M: Cell cycle,
CDKs and cancer: a changing paradigm. Nat Rev Cancer. 9:153–166.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Deshpande A, Sicinski P and Hinds PW:
Cyclins and CDKs in development and cancer: a perspective.
Oncogene. 24:2909–2915. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fu M, Wang C, Li Z, Sakamaki T and Pestell
RG: Minireview: cyclin D1: normal and abnormal functions.
Endocrinology. 145:5439–5447. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Musgrove EA, Caldon CE, Barraclough J,
Stone A and Sutherland RL: Cyclin D as a therapeutic target in
cancer. Nat Rev Cancer. 11:558–572. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Roy PG, Pratt N, Purdie CA, Baker L,
Ashfield A, Quinlan P and Thompson AM: High CCND1 amplification
identifies a group of poor prognosis women with estrogen receptor
positive breast cancer. Int J Cancer. 127:355–360. 2010.PubMed/NCBI
|
|
7
|
Yu Q, Geng Y and Sicinski P: Specific
protection against breast cancers by cyclin D1 ablation. Nature.
411:1017–1021. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Choi YJ, Li X, Hydbring P, Sanda T,
Stefano J, Christie AL, Signoretti S, Look AT, Kung AL, von Boehmer
H and Sicinski P: The requirement for cyclin D function in tumor
maintenance. Cancer Cell. 22:438–451. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Malumbres M: Cell cycle-based therapies
move forward. Cancer Cell. 22:419–420. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Beroukhim R, Mermel CH, Porter D, et al:
The landscape of somatic copy-number alteration across human
cancers. Nature. 463:899–905. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim JK and Diehl JA: Nuclear cyclin D1: an
oncogenic driver in human cancer. J Cell Physiol. 220:292–306.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Scott AM, Wolchok JD and Old LJ: Antibody
therapy of cancer. Nat Rev Cancer. 12:278–287. 2012. View Article : Google Scholar
|
|
13
|
Elvin JG, Couston RG and van der Walle CF:
Therapeutic antibodies: market considerations, disease targets and
bioprocessing. Int J Pharm. 440:83–98. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Stewart CS, MacKenzie CR and Hall JC:
Isolation, characterization and pentamerization of alpha-cobrotoxin
specific single-domain antibodies from a naïve phage display
library: preliminary findings for antivenom development. Toxicon.
49:699–709. 2007.PubMed/NCBI
|
|
15
|
Wen S, Zhang X, Liu Y, Zhang QQ, Liu XJ
and Liang JS: Selection of a single chain variable fragment
antibody against ivermectin from a phage displayed library. J Agric
Food Chem. 58:5387–5391. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Holliger P and Hudson PJ: Engineered
antibody fragments and the rise of single domains. Nat Biotechnol.
23:1126–1136. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dai H, Gao H, Zhao X, Dai L, Zhang X, Xiao
N, Zhao R and Hemmingsen SM: Construction and characterization of a
novel recombinant single-chain variable fragment antibody against
white spot syndrome virus from shrimp. J Immunol Methods.
279:267–275. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Weisser NE and Hall JC: Applications of
single-chain variable fragment antibodies in therapeutics and
diagnostics. Biotechnol Adv. 27:502–520. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhou LH, Zhu X, Cao YH, Wang L, Chen Y, Du
BR and Li GY: Construction of expression vector for anti-cyclin D1
intrabody AD5N and its inhibitory effects on cell proliferation of
breast cancer. Chin J Immunol. 24:703–706. 2008.
|
|
20
|
Zhou LH, Zhu X, Cao YH, Chen Y, Tian Y,
Wang L and Li GY: Effects of anti-cyclin D1 intrabody AD5N on HeLa
cells of uterine cervix cancer. Chin J Clin Oncol. 35:942–944.
2008.
|
|
21
|
Qiao YY, Wang Y, Chen XS, Wang YX and Hua
B: Construction of a large single-chain phage antibody library.
Chin J Microbiol Immunol. 24:194–197. 2004.
|
|
22
|
Li GY, Zou DS and Zhou LH: Expression and
purification of recombinant human cyclin D1 in E. coli BL21.
J Jilin Univ. 44:839–843. 2006.
|
|
23
|
Beatty JD, Beatty BG and Vlahos WG:
Measurement of monoclonal antibody affinity by non-competitive
enzyme immunoassay. J Immunol Methods. 100:173–179. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ding Z, Wu CJ, Chu GC, et al:
SMAD4-dependent barrier constrains prostate cancer growth and
metastatic progression. Nature. 470:269–273. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bienvenu F, Jirawatnotai S, Elias JE, et
al: Transcriptional role of cyclin D1 in development revealed by a
genetic-proteomic screen. Nature. 463:374–378. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bartek J and Lukas J: DNA repair: Cyclin
D1 multitasks. Nature. 474:171–172. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen
NB and Hamid M: scFv antibody: principles and clinical application.
Clin Dev Immunol. 2012:9802502012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhu X, Wang D, Li S, Xiao Q, Tao K, Hu J,
Cao W and Feng W: Expression of a humanized single-chain variable
fragment antibody targeting chronic myeloid leukemia cells in
Escherichia coli and its characterization. Int J Mol Med.
29:939–945. 2012.PubMed/NCBI
|
|
29
|
Sushma K, Vijayalakshmi MA, Krishnan V and
Satheeshkumar PK: Cloning, expression, purification and
characterization of a single chain variable fragment specific to
tumor necrosis factor alpha in Escherichia coli. J
Biotechnol. 156:238–244. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang T, Yang L, Chai W, Li R, Xie J and
Niu B: A strategy for high-level expression of a single-chain
variable fragment against TNFα by subcloning antibody variable
regions from the phage display vector pCANTAB 5E into pBV220.
Protein Expr Purif. 76:109–114. 2011.PubMed/NCBI
|
|
31
|
Abdolalizadeh J, Nouri M, Zolbanin JM,
Baradaran B, Barzegari A and Omidi Y: Downstream characterization
of anti-TNF-α single chain variable fragment antibodies. Hum
Antibodies. 21:41–48. 2012.
|
|
32
|
Adams GP and Schier R: Generating improved
single-chain Fv molecules for tumor targeting. J Immunol Methods.
231:249–260. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yuan W and Parrish CR: Comparison of two
single-chain antibodies that neutralize canine parovirus: analysis
of an antibody-combining site and mechanisms of neutralization.
Virology. 269:471–480. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Neri P, Shigemori N, Hamada-Tsutsumi S,
Tsukamoto K, Arimitsu H, Shimizu T, Akahori Y, Kurosawa Y and Tsuji
T: Single chain variable fragment antibodies against Shiga toxins
isolated from a human antibody phage display library. Vaccine.
29:5340–5346. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Schier R, McCall A, Adams GP, Marshall KW,
Merritt H, Yim M, Crawford RS, Weiner LM, Marks C and Marks JD:
Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by
molecular evolution of the complementarity determining regions in
the center of the antibody binding site. J Mol Biol. 263:551–567.
1996. View Article : Google Scholar
|
